期刊
FUTURE ONCOLOGY
卷 14, 期 27, 页码 2861-2874出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0711
关键词
afatinib; osimertinib; NSCLC; sequential; T790M
类别
资金
- Boehringer Ingelheim
- Astra Zeneca
- Pfizer
- Novartis
- Takeda
- Merck
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials& methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment 10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据